YAFO Acts as Exclusive Financial Advisor for Flexion Therapeutics in its Licensing-out Transaction with Tainuo

雅法担任Flexion Therapeutics独家顾问,完成与泰诺医药商业许可交易

Transaction Overview 交易概览

Flexion signs exclusive license agreement with Hong Kong Tainuo Pharma Ltd. (HK Tainuo) and Jiangsu Tainuo Pharmaceutical Co. Ltd. (Jiangsu Tainuo) for the development and commercialization of ZILRETTA® in Greater China

Flexion宣布与香港泰诺制药有限公司(“ 香港泰诺”)和江苏泰诺医药有限公司(以下简称“江苏泰诺”)在大中华区签订ZILRETTA的许可协议

Shanghai YAFO Capital (YAFO Life Science) acted as the exclusive financial advisor on this transaction for Flexion

上海雅法资本(雅法全球医疗)在此次交易中担任Flexion公司的独家财务顾问

License agreement provides Flexion with $10 million upfront payment, up to $32.5 million in milestones, and additional fees for the supply of ZILRETTA

Flexion将获得1000万美元的首付款,总额高达3250万美元的开发,注册和商业销售里程碑付款。

Flexion Press Release Link:

https://www.globenewswire.com/news-release/2020/04/01/2009879/0/en/Flexion-Therapeutics-Announces-ZILRETTA-License-Agreement-and-Provides-Business-Update-Amid-Coronavirus-Pandemic.html

About The Asset 交易资产介绍

On October 6, 2017, ZILRETTA was approved by the U.S. FDA as the first and only extended-release intra-articular therapy for patients confronting osteoarthritis-related knee pain. ZILRETTA employs proprietary microsphere technology combining triamcinolone acetonide — a commonly administered, short-acting corticosteroid — with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief. The pivotal Phase 3 trial on which the approval of ZILRETTA was based showed that ZILRETTA significantly reduced knee pain for 12 weeks, with some people experiencing pain relief through Week 16.

ZILRETTA是一种用于膝关节炎的止痛药物。该产品在2017年底获得FDA批准,是目前首个也是唯一一款FDA批准的用于缓解膝关节炎疼痛的关节腔内注射的缓释药物。ZILRETTA的核心技术是基于聚乳酸-羟基乙酸共聚物(PLGA)微球的缓释给药技术,该技术可使常用的短效糖皮质激素曲安耐得缓慢的在关节腔内释放,为膝骨关节炎患者提供长效的镇痛效果。ZILRETTA的批准是基于优秀的三期临床试验结果,该结果表明多数患者在12周内可有明显的镇痛效果,部分患者的镇痛效果可持续至第16周。

About Flexion Therapeutics (Nasdaq: FLXN)

Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun.

Flexion Therapeutics,Inc.(纳斯达克股票代码:FLXN)是一家生物制药公司,致力于开发和商业化用于治疗骨骼肌肉疾病的新型局部疗法。该公司的主要产品ZILRETTA是一款治疗膝关节炎的长效缓释型糖皮质激素注射剂。公司的核心价值观是专注,创新,坚韧,透明和有趣。

About HK Tainuo 香港泰诺

Hong Kong Tainuo Pharma Limited (HK Tainuo) is a pharmaceutical company located in Hong Kong, China, focusing on commercializing innovative and cutting-edge therapies and medications to address the unmet medical needs in the Asia Pacific region. With its strong sales and marketing expertise and capabilities and its nationwide commercial presence and distribution network, HK Tainuo is specialized in marketing and commercializing the OA, CV and CNS brands & generics across China, among others.

香港泰诺医药开发有限公司是一家位于中国香港的医药公司,致力于创新和尖端的疗法药物的商业化,以满足亚太地区尚未满足的医疗需求。凭借强大的销售和营销专业知识与能力以及遍布全国的业务网络和分销网络,香港泰诺在中国各地区对骨关节炎、心血管、CNS等领域的原研及仿制药品进行专业的营销和商业化活动。

About YAFO Life Science 雅法全球医疗

YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and medtech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com

雅法全球医疗(YAFO Life Science)是雅法资本旗下的医疗大健康部门,专注于帮助具有“中国角度”的海外医药、医疗器械企业在中国的融资、授权和战略合作;为中国医疗企业提供产品全球授权、海外市场研究服务,寻找海外投资并购标的,及产品商业合作。雅法全球医疗核心合伙人团队均为华尔街资深投行人士或具有跨国药企工作经验;雅法庞大的海外的区域合伙人团队,均具20+年医药行业及交易经验,覆盖美国、日本 、欧洲等主要全球医药创新区域。项目合作请联系:黎琦 | BD Director | 13621979227 | qli@yafocapital.com

YAFO Upcoming Events - ACCESS CHINA BD Forum & Online Partnering

For more information please contact:

Fan Zheng 郑帆

Managing Director

fzheng@yafocapital.com

Qi Li 黎琦

BD Director

qli@yafocapital.com

Kun Tao, CFA

Partner, Head of U.S. Business

ktao@yafocapital.com